189 related articles for article (PubMed ID: 28525644)
1. Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents.
Kim SH; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Lee JW
Med Mycol; 2018 Feb; 56(2):197-206. PubMed ID: 28525644
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough bloodstream infections in critically ill non-neutropenic patients: higher incidence and better survival than non-breakthrough infections.
Papadimitriou-Olivgeris M; Kolonitsiou F; Solomou A; Karamouzos V; Anastassiou ED; Christofidou M; Spiliopoulou I; Fligou F; Marangos M
J Med Microbiol; 2019 Oct; 68(10):1544-1551. PubMed ID: 31436523
[No Abstract] [Full Text] [Related]
3. Fatal Disseminated Infection by Trichosporon asahii Under Voriconazole Therapy in a Patient with Acute Myeloid Leukemia: A Review of Breakthrough Infections by Trichosporon spp.
Ramírez I; Moncada D
Mycopathologia; 2020 Apr; 185(2):377-388. PubMed ID: 31853871
[TBL] [Abstract][Full Text] [Related]
4. Pattern of bloodstream infections in patients with hematological malignancies in a tertiary care centre.
Bansal S; Advani SH
Indian J Cancer; 2014; 51(4):447-9. PubMed ID: 26842155
[TBL] [Abstract][Full Text] [Related]
5. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections.
Tang Y; Cheng Q; Yang Q; Liu J; Zhang D; Cao W; Liu Q; Zhou T; Zeng H; Zhou L; Wang Q; Wei H; Li X
Infection; 2018 Aug; 46(4):513-521. PubMed ID: 29767394
[TBL] [Abstract][Full Text] [Related]
7. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection.
Sipsas NV; Lewis RE; Tarrand J; Hachem R; Rolston KV; Raad II; Kontoyiannis DP
Cancer; 2009 Oct; 115(20):4745-52. PubMed ID: 19634156
[TBL] [Abstract][Full Text] [Related]
8. Factors related to outcome of bloodstream infections due to Candida parapsilosis complex.
Barchiesi F; Orsetti E; Osimani P; Catassi C; Santelli F; Manso E
BMC Infect Dis; 2016 Aug; 16():387. PubMed ID: 27507170
[TBL] [Abstract][Full Text] [Related]
9. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.
Myoken Y; Kyo T; Fujihara M; Sugata T; Mikami Y
Haematologica; 2004 Mar; 89(3):378-80. PubMed ID: 15020289
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study.
Schuster MG; Meibohm A; Lloyd L; Strom B
J Infect; 2013 Mar; 66(3):278-84. PubMed ID: 23174708
[TBL] [Abstract][Full Text] [Related]
12. Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital.
Åttman E; Aittoniemi J; Sinisalo M; Vuento R; Lyytikäinen O; Kärki T; Syrjänen J; Huttunen R
Leuk Lymphoma; 2015; 56(12):3370-7. PubMed ID: 25813080
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.
Kara Ö; Zarakolu P; Aşçioğlu S; Etgül S; Uz B; Büyükaşik Y; Akova M
Infect Dis (Lond); 2015; 47(10):686-93. PubMed ID: 26024284
[TBL] [Abstract][Full Text] [Related]
14. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
15. Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center.
Pande A; Non LR; Romee R; Santos CA
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28099778
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India.
Dewan E; Biswas D; Kakati B; Verma SK; Kotwal A; Oberoi A
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):99-105. PubMed ID: 26173033
[TBL] [Abstract][Full Text] [Related]
17. A clinical analysis of
Yang B; Wei Z; Wu M; Lai Y; Zhao W
Front Microbiol; 2023; 14():1092175. PubMed ID: 37520379
[TBL] [Abstract][Full Text] [Related]
18. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated with Breakthrough Fungemia Caused by
Kimura M; Asano-Mori Y; Sakoh T; Abe M; Ueno K; Hoshino Y; Nakamura S; Umeyama T; Yamagoe S; Miyazaki Y; Baba M; Okada C; Ogura S; Mitsuki T; Yamaguchi K; Yuasa M; Kaji D; Kageyama K; Nishida A; Taya Y; Ishiwata K; Takagi S; Yamamoto H; Yamamoto G; Uchida N; Wake A; Taniguchi S; Araoka H
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0208121. PubMed ID: 35041512
[TBL] [Abstract][Full Text] [Related]
20. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Minari A; Hachem R; Raad I
Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
